Progenics Pharmaceuticals
(PGNX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2002 | 06-2002 | 03-2002 | 12-2001 | 09-2001 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -13,768 | -7,356 | -2,001 | -1,898 | 2,581 |
| Depreciation Amortization | 1,665 | 1,056 | 495 | 1,134 | 753 |
| Accounts receivable | 136 | -267 | -120 | 2,274 | 1,731 |
| Other Working Capital | -3,504 | -1,598 | -685 | 163 | -184 |
| Other Operating Activity | 2,228 | 1,585 | 774 | 393 | 320 |
| Operating Cash Flow | $-13,243 | $-6,581 | $-1,537 | $2,066 | $5,200 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 9,834 | 6,240 | 4,201 | 3,335 | 5,676 |
| PPE Investments | -1,175 | -953 | -397 | -1,265 | -923 |
| Other Investing Activity | -121 | -121 | -120 | 0 | 0 |
| Investing Cash Flow | $8,538 | $5,167 | $3,684 | $2,070 | $4,753 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | -12 | -6 |
| Common Stock Issued | 1,116 | 859 | 580 | 1,007 | 784 |
| Financing Cash Flow | $1,116 | $859 | $580 | $995 | $778 |
| Beginning Cash Position | 10,760 | 10,760 | 10,760 | 5,629 | 5,629 |
| End Cash Position | 7,171 | 10,204 | 13,487 | 10,760 | 16,360 |
| Net Cash Flow | $-3,589 | $-556 | $2,727 | $5,131 | $10,731 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,243 | -6,581 | -1,537 | 2,066 | 5,200 |
| Capital Expenditure | -1,175 | -953 | -397 | -1,265 | -923 |
| Free Cash Flow | -14,418 | -7,534 | -1,934 | 801 | 4,277 |